Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective hoisted by equities research analysts at UBS Group from $174.00 to $193.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 43.37% from the company’s […]
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) were down 5.3% on Wednesday . The stock traded as low as $132.58 and last traded at $133.02. Approximately 153,432 shares were traded during trading, a decline of 81% from the average daily volume of 812,679 shares. The stock had previously closed at $140.48. Analyst […]
Westfield Capital Management Co. LP decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 594,437 shares of the company’s stock after selling 54,855 shares during the period. Westfield Capital Management Co. LP […]